FunPep Company Limited (JP:4881)
:4881
Want to see JP:4881 full AI Analyst Report?
4881 Stock Chart & Stats
¥79.00
¥1.00(0.72%)
At close: 4:00 PM EST
¥79.00
¥1.00(0.72%)
Day’s Range― - ―
52-Week Range¥57.00 - ¥130.00
Previous CloseN/A
Volume532.20K
Average Volume (3M)245.82K
Market Cap
¥3.04B
Enterprise Value¥824.17M
Total Cash (Recent Filing)¥2.33B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta1.04
Next Earnings
Aug 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-41.98
Shares Outstanding50,666,700
10 Day Avg. Volume262,310
30 Day Avg. Volume245,823
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)2.13
Price to Sales (P/S)9943.96
P/FCF Ratio-2.25
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-19.9
Revenue Forecast (FY)¥300.00M
Bulls Say, Bears Say
Bulls Say
Zero Debt / Clean Balance SheetHaving zero reported debt materially reduces refinancing risk and preserves strategic optionality for an early‑stage biotech. This capital structure gives management flexibility to pursue R&D, licensing deals or milestone-focused partnerships without immediate leverage constraints, a durable advantage while they seek non-debt funding.
Proprietary Peptide Platform And Immunotherapy FocusA proprietary peptide platform focused on immunotherapies is a structural competitive asset: it can generate multiple programs, improve speed of candidate discovery, and attract partners. Over 2–6 months this confers durable pipeline optionality and licensing appeal if scientific validation and collaborations progress.
Licensing & Partnership-driven Revenue ModelAn asset-light, licensing-centric business model reduces capital intensity versus full commercial launches. Durable revenue streams from milestones and royalties can scale without proportionate capex, making the firm attractive to partners and enabling continuation of R&D through non-dilutive or milestone-based funding.
Bears Say
Severe Revenue Collapse In 2025A ~94% year‑over‑year revenue decline is a material structural red flag: it signals lost partner income, failed deals or product disruptions that undermine recurring licensing cash flows. Such a collapse weakens the company's ability to fund R&D and increases likelihood of dilution or asset sales over the medium term.
Accelerating Cash Burn And Negative Operating Cash FlowWorsening operating cash flow and persistent negative free cash flow indicate the business is not self‑funding and cash consumption accelerated in 2025. Over several months this raises financing urgency, increases dilution risk if equity raises are needed, and constrains long‑term R&D and trial funding choices.
Deepening Net Losses And Material Equity DeclineSustained widening losses and a marked drop in shareholders' equity reflect ongoing value erosion. This reduces financial resilience and investor capacity to absorb further dilution, making future capital raises more costly and threatening the company's ability to sustain long‑term development programs without strategic partnerships or restructuring.
4881 FAQ
What was FunPep Company Limited’s price range in the past 12 months?
FunPep Company Limited lowest stock price was ¥57.00 and its highest was ¥130.00 in the past 12 months.
What is FunPep Company Limited’s market cap?
FunPep Company Limited’s market cap is ¥3.04B.
When is FunPep Company Limited’s upcoming earnings report date?
FunPep Company Limited’s upcoming earnings report date is Aug 07, 2026 which is in 53 days.
How were FunPep Company Limited’s earnings last quarter?
FunPep Company Limited released its earnings results on May 12, 2026. The company reported -¥7.03 earnings per share for the quarter, missing the consensus estimate of N/A by -¥7.03.
Is FunPep Company Limited overvalued?
According to Wall Street analysts FunPep Company Limited’s price is currently Overvalued.
Does FunPep Company Limited pay dividends?
FunPep Company Limited does not currently pay dividends.
What is FunPep Company Limited’s EPS estimate?
FunPep Company Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does FunPep Company Limited have?
FunPep Company Limited has 50,666,700 shares outstanding.
What happened to FunPep Company Limited’s price movement after its last earnings report?
FunPep Company Limited reported an EPS of -¥7.03 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.429%.
Which hedge fund is a major shareholder of FunPep Company Limited?
Currently, no hedge funds are holding shares in JP:4881
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
FunPep Company Limited
FunPep Company Limited specializes in the discovery and advancement of pharmaceutical drugs, functional cosmetics, and medical devices, leveraging its core technology in functional peptides. The company's development pipeline prominently features SR-0379, a functional peptide designed to address skin ulcers. FunPep is advancing FPP003, an antibody-inducing peptide, which is undergoing Phase II clinical trials for psoriasis in Australia and for ankylosing spondylitis in Japan. Another antibody-inducing peptide, FPP004X, is also in development, targeting pollinosis. Additionally, the company is working on FPP006, a corona peptide vaccine, and FPP005, an antibody-inducing peptide for psoriasis. Established in 2013, FunPep Company Limited operates from its headquarters in Tokyo, Japan.
Technical Analysis
Peptidream
―
NanoCarrier Co., Ltd.
―
Kohjin Bio Co.,Ltd.
―
Linical Co., Ltd.
―
Immuno-Biological Laboratories Co., Ltd.
―